Nov 23 2009
CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) and All Business Machines, Inc. ("ABMI") (www.abmicorp.com) announce that the ValiMed™ MVS (Medication Validation System) and ID2 Meth Scanner™ product lines by CDEX have been placed on the ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between the patient and errors made in the compounding of high risk medications and guards against narcotic diversion. Both are now available to the Government markets through the ABMI GSA Schedule.
"Medical studies demonstrate that human errors in compounding of high-risk medications occur all too frequently and result in permanent harm to patients," said Karl Ross, President of ABMI. "ValiMed MVS provides an answer that is saving lives today. We are pleased to partner with CDEX in bringing this lifesaving product line, as well as the ID2 Meth Scanner, to the Government market on our GSA Contract Schedule. There has been a great deal of interest for both products and we now have a contract vehicle to make it happen."
"We are very pleased to be on the GSA Schedule and look forward to working more closely with ABMI in Government markets," said Malcolm Philips, CDEX CEO. "Interest in our two product lines continues to be strong. Being placed on the GSA Schedule is happening at the right time with a thawing in the economic markets. We see 2010 shaping up to be a very good year for CDEX sales."